DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
13F Reported Value
ⓘ$8.5B
Holdings
82
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) disclosed 82 positions worth $8.5B in its Form 13F-HR for Q1 2026, led by $NUVL (Nuvalent, Inc.) at 20.9% of the equity portfolio. During the quarter the fund opened 10 new positions and exited 77 — including a new stake in $SNDX and a full exit from $PHR. The portfolio is most concentrated in Healthcare (88.7% of disclosed assets). All figures are sourced directly from DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)’s Form 13F-HR filing with the SEC under CIK 1009258.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$1.8B17,248,450 sh BROOKDALE SR LIVING INC
—Quality
$505.4M306,885,000 sh- —
Quality
$348.1M9,043,903 sh - $310.4M963,351 sh
- 47.1
Quality
$273.0M20,206,170 sh - 80.1
Quality
$271.0M457,000 sh - —
Quality
$223.4M2,297,000 sh - 32.7
Quality
$209.4M70,000,000 sh ARROWHEAD PHARMACEUTICALS IN
—Quality
$207.2M200,000,000 sh- —
Quality
$195.6M1,714,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Nuvalent, Inc.$NUVL | — | $1.8B | 17,248,450 |
| BROOKDALE SR LIVING INC | — | $505.4M | 306,885,000 |
 Cogent Biosciences, Inc.$COGT | — | $348.1M | 9,043,903 |
 Praxis Precision Medicines, Inc.$PRAX | — | $310.4M | 963,351 |
 Viatris Inc$VTRS | 47.1 | $273.0M | 20,206,170 |
 UNITED THERAPEUTICS Corp$UTHR | 80.1 | $271.0M | 457,000 |
 Revolution Medicines, Inc.$RVMD | — | $223.4M | 2,297,000 |
 Mirum Pharmaceuticals, Inc.$MIRM | 32.7 | $209.4M | 70,000,000 |
| ARROWHEAD PHARMACEUTICALS IN | — | $207.2M | 200,000,000 |
 Celcuity Inc.$CELC | — | $195.6M | 1,714,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 82 positions.
Showing top 10 of 82 holdings.
Sector Allocation
Healthcare
$7.5B
Other
$779.9M
Technology
$174.2M
Full Holdings — DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Q1 2026)
All 82 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NUVL | Nuvalent, Inc. | $1.8B | 20.9% | +0% | — |
| 2 | — | BROOKDALE SR LIVING INC | $505.4M | 6.0% | +0% | — |
| 3 | $COGT | Cogent Biosciences, Inc. | $348.1M | 4.1% | +0% | — |
| 4 | $PRAX | Praxis Precision Medicines, Inc. | $310.4M | 3.7% | +7% | — |
| 5 | $VTRS | Viatris Inc | $273.0M | 3.2% | +0% | 47.1 |
| 6 | $UTHR | UNITED THERAPEUTICS Corp | $271.0M | 3.2% | +7% | 80.1 |
| 7 | $RVMD | Revolution Medicines, Inc. | $223.4M | 2.6% | -21% | — |
| 8 | $MIRM | Mirum Pharmaceuticals, Inc. | $209.4M | 2.5% | +0% | 32.7 |
| 9 | — | ARROWHEAD PHARMACEUTICALS IN | $207.2M | 2.4% | NEW | — |
| 10 | $CELC | Celcuity Inc. | $195.6M | 2.3% | +0% | — |
| 11 |  $CNC | CENTENE CORP | $193.7M | 2.3% | -8% | 52.7 |
| 12 |  $LRMR | Larimar Therapeutics, Inc. | $160.2M | 1.9% | +16% | — |
| 13 |  $BKD | Brookdale Senior Living Inc. | $159.2M | 1.9% | +0% | 43.1 |
| 14 |  $VERA | Vera Therapeutics, Inc. | $149.7M | 1.8% | -8% | — |
| 15 |  $IONS | IONIS PHARMACEUTICALS INC | $148.7M | 1.8% | +0% | 37.1 |
| 16 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $143.2M | 1.7% | +5% | 37.2 |
| 17 |  $INSP | Inspire Medical Systems, Inc. | $139.4M | 1.6% | +80% | 46 |
| 18 |  $LEGN | Legend Biotech Corp | $139.1M | 1.6% | +30% | 44.2 |
| 19 |  $AHCO | AdaptHealth Corp. | $136.6M | 1.6% | +0% | 47.9 |
| 20 |  $NAMS | NewAmsterdam Pharma Co N.V. | $136.5M | 1.6% | +2% | — |
| 21 |  $ACHC | Acadia Healthcare Company, Inc. | $105.7M | 1.3% | +0% | 49.3 |
| 22 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $98.6M | 1.2% | -14% | 74.4 |
| 23 |  $CPRX | CATALYST PHARMACEUTICALS, INC. | $97.6M | 1.1% | -20% | 78.7 |
| 24 |  $INDV | Indivior Pharmaceuticals, Inc. | $94.4M | 1.1% | -9% | 64.6 |
| 25 |  $XENE | Xenon Pharmaceuticals Inc. | $94.0M | 1.1% | +198% | 12.9 |
| 26 | $IONS | IONIS PHARMACEUTICALS INC | $90.6M | 1.1% | +0% | 37.1 |
| 27 |  $PHVS | Pharvaris N.V. | $88.3M | 1.0% | +0% | — |
| 28 |  $SNDX | Syndax Pharmaceuticals Inc | $88.3M | 1.0% | NEW | 30 |
| 29 |  $TNGX | Tango Therapeutics, Inc. | $86.8M | 1.0% | +43% | 26.9 |
| 30 |  $ALHC | Alignment Healthcare, Inc. | $85.9M | 1.0% | +0% | 63 |
| 31 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $85.6M | 1.0% | NEW | 26.8 |
| 32 |  $PFE | PFIZER INC | $85.4M | 1.0% | NEW | 69 |
| 33 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $80.4M | 0.9% | -48% | 75.4 |
| 34 |  $DAWN | Day One Biopharmaceuticals, Inc. | $79.8M | 0.9% | +0% | 42.6 |
| 35 |  $SVRA | Savara Inc | $74.1M | 0.9% | +0% | — |
| 36 | — | ZENAS BIOPHARMA INC | $67.3M | 0.8% | NEW | — |
| 37 |  $EHAB | Enhabit, Inc. | $66.9M | 0.8% | +0% | 54.8 |
| 38 |  $NEO | NEOGENOMICS INC | $66.7M | 0.8% | +0% | 34.6 |
| 39 |  $GMAB | GENMAB A/S | $66.1M | 0.8% | NEW | — |
| 40 |  $BIO | BIO-RAD LABORATORIES, INC. | $63.0M | 0.7% | +0% | 40.3 |
| 41 |  $LNTH | Lantheus Holdings, Inc. | $62.8M | 0.7% | +0% | 66.9 |
| 42 |  $SPRY | ARS Pharmaceuticals, Inc. | $60.3M | 0.7% | +0% | 29.7 |
| 43 |  $STOK | Stoke Therapeutics, Inc. | $59.4M | 0.7% | +0% | 53.4 |
| 44 |  $NVST | Envista Holdings Corp | $56.1M | 0.7% | -3% | 49.8 |
| 45 |  $IDYA | IDEAYA Biosciences, Inc. | $51.0M | 0.6% | -29% | 10.5 |
| 46 |  $BLTE | BELITE BIO, INC | $48.5M | 0.6% | +30% | — |
| 47 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $48.1M | 0.6% | NEW | 74.1 |
| 48 |  $KYMR | Kymera Therapeutics, Inc. | $46.7M | 0.6% | +0% | 29.2 |
| 49 |  $CERT | Certara, Inc. | $44.5M | 0.5% | +0% | 47 |
| 50 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $43.7M | 0.5% | +0% | — |
| 51 |  $IRON | Disc Medicine, Inc. | $42.0M | 0.5% | +29% | — |
| 52 |  $LIVN | LivaNova PLC | $40.0M | 0.5% | +0% | — |
| 53 |  $SION | Sionna Therapeutics, Inc. | $38.9M | 0.5% | +0% | — |
| 54 |  $CDNA | CareDx, Inc. | $38.0M | 0.5% | +0% | 44.8 |
| 55 |  $GPCR | Structure Therapeutics Inc. | $37.0M | 0.4% | +0% | — |
| 56 |  $IMCR | Immunocore Holdings plc | $27.0M | 0.3% | +0% | — |
| 57 |  $VCYT | VERACYTE, INC. | $23.4M | 0.3% | +0% | 59.5 |
| 58 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $22.5M | 0.3% | +0% | 60.9 |
| 59 |  $EMBC | Embecta Corp. | $22.4M | 0.3% | -8% | 60.2 |
| 60 |  $TYRA | Tyra Biosciences, Inc. | $21.0M | 0.3% | NEW | — |
| 61 |  $FHTX | Foghorn Therapeutics Inc. | $21.0M | 0.3% | +20% | 11.2 |
| 62 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $20.7M | 0.2% | NEW | — |
| 63 |  $CMPX | Compass Therapeutics, Inc. | $19.1M | 0.2% | +0% | — |
| 64 |  $MNPR | Monopar Therapeutics | $17.7M | 0.2% | +90% | — |
| 65 |  $KYTX | Kyverna Therapeutics, Inc. | $17.3M | 0.2% | +0% | — |
| 66 |  $SGP | SpyGlass Pharma, Inc. | $14.3M | 0.2% | NEW | — |
| 67 |  $BBNX | Beta Bionics, Inc. | $13.3M | 0.2% | +41% | 22.8 |
| 68 |  $TSHA | Taysha Gene Therapies, Inc. | $12.2M | 0.1% | +0% | 4.1 |
| 69 |  $TOI | Oncology Institute, Inc. | $10.3M | 0.1% | +0% | 37.8 |
| 70 |  $CGEM | Cullinan Therapeutics, Inc. | $5.5M | 0.1% | +0% | — |
| 71 |  $ANNX | Annexon, Inc. | $3.2M | 0.0% | +0% | — |
| 72 |  $ALEC | Alector, Inc. | $2.3M | 0.0% | +0% | 8.9 |
| 73 | $NAMS | NewAmsterdam Pharma Co N.V. | $1.9M | 0.0% | +0% | — |
| 74 |  $EW | Edwards Lifesciences Corp | $1.1M | 0.0% | +0% | 67.6 |
| 75 |  $PHGE | BiomX Inc. | $492,795 | 0.0% | +0% | — |
| 76 |  $MANE | Veradermics, Inc | $315,750 | 0.0% | NEW | — |
| 77 |  $HUM | HUMANA INC | $158,999 | 0.0% | +0% | 82 |
| 78 | $TOI | Oncology Institute, Inc. | $54,750 | 0.0% | +0% | 37.8 |
| 79 |  $QSI | Quantum-Si Inc | $36,200 | 0.0% | +0% | 21.2 |
| 80 |  $PMVP | PMV Pharmaceuticals, Inc. | $10,900 | 0.0% | +0% | — |
| 81 |  $SRZN | Surrozen, Inc./DE | $2,667 | 0.0% | +0% | — |
| 82 |  $MYGN | MYRIAD GENETICS INC | $2,273 | 0.0% | +0% | 30.2 |
New Positions (10)
$SNDX Syndax Pharmaceuticals Inc$88.3M$DNTH Dianthus Therapeutics, Inc. /DE/$85.6M$PFE PFIZER INC$85.4M$GMAB GENMAB A/S$66.1M$BMRN BIOMARIN PHARMACEUTICAL INC$48.1M$TYRA Tyra Biosciences, Inc.$21.0M$DRUG BRIGHT MINDS BIOSCIENCES INC.$20.7M$SGP SpyGlass Pharma, Inc.$14.3M$MANE Veradermics, Inc$315,750Exited Positions (77)
$PHR Phreesia, Inc.
$MRNAPUT Moderna, Inc.
$VTR Ventas, Inc.
$SYRE Spyre Therapeutics, Inc.
$EWTX Edgewise Therapeutics, Inc.
$CRMD CorMedix Inc.
$MDLN Medline Inc.
$OMDA Omada Health, Inc.
$CALC CalciMedica, Inc.
$PBH Prestige Consumer Healthcare Inc.
$VEEV VEEVA SYSTEMS INC
$RDNT RadNet, Inc.
$LH LABCORP HOLDINGS INC.
$ENOV Enovis CORP
$DGX QUEST DIAGNOSTICS INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) including:
Track DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
13F Pro is an AI hedge fund tracker and stock research platform. For DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (SEC CIK: 1009258), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.